Advanced/recurrent cancer (pancreatic cancer, colon cancer, biliary tract cancer, esophageal cancer, pharynx cancer, breast cancer etc.)
Conditions
Interventions
HSP105 peptide-pulsed dendritic cells are injected on day
Sponsors
The University of Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age >= 20 years at informed consent. 2) Patients who recognized HSP105 expression on tumor tissue. 3) HLA-A*24:02, 02:01, 02:06 or 02:07 positive. 4) Performance status is 0-1. 5) No serious abnormality in heart, lung, bone marrow, liver, and renal functions.
Exclusion criteria
Exclusion criteria: 1) Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; 2) Serious drug allergy; 3) Difficult infections to control; 4) Serious cardiac disease; 5) Active autoimmune diseases; 6) Other cancers; 7) Continuous systemic administration of steroids and/or immunosuppressants within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological responses Antitumor effect Overall survival Progression-free survival | — |
Countries
Japan
Contacts
Public ContactKazuhiro Kakimi
The University of Tokyo Hospital Department of Immunotherapeutics
Outcome results
None listed